Taima is a token intended to be used as a payment token. Solana is based on the blockchain. It will allow the group’s client to take stock and production of Origami Pharma’s factories. In proportion to the production capacity of origami, the demand for Taima will increase, which will increase the price of Taima. Essentially, Taima will be sold at the supply and demand price. The creation of each plant will provide Taima with a new annual demand by cannabis distribution companies that will want to buy from Origami. Therefore, Taima will be a payment token that will be directly linked to the cannabis produced by Origami.
About Taima
FIRST TOKEN LINK ON REAL VALUE CREATION
Taima is a token intended to be used as a payment token. Solana is based on the blockchain. It will allow the group’s client to take stock and production of Origami Pharma’s factories. In proportion to the production capacity of origami, the demand for Taima will increase, which will increase the price of Taima. Essentially, Taima will be sold at the supply and demand price. The creation of each plant will provide Taima with a new annual demand by cannabis distribution companies that will want to buy from Origami. Therefore, Taima will be a payment token that will be directly linked to the cannabis produced by Origami.
The principle of taima is the principle of created supply and demand. Linking the value creation created by the repeated production of medicinal or recreational cannabis plants to Taima will allow it to expand. While the market is facing a shortage of supply, demand is constantly expanding.
Demand for medicinal and recreational cannabis far exceeds the actual production capacity of the market. Every ton of production is expected to be sold.
For a flower production capacity of 250 million Euros per year, it will take a counter value of 250,000,000 in Taima to obtain it. Distributors will therefore have to buy their equivalent in Taima. The million Taima in circulation will represent the value of demand, which will total 250 million for this production year.
The Origami Group is planning an expansion plan that will allow its production capacity to produce more tons per year, so the demand for Taima will increase steadily. This will directly affect the number of Taima in circulation as Ashita does not plan to release more Taima in the coming years.
In the case of softcap the initial production capacity would be 50 tonnes per year. In the case of Hardcap, Origami will start with an initial capacity of 500 tons per year. Taima’s demand for 50 tons will be equivalent to €250 million, and demand for 500 tons will be €2.5 billion. Taima price will get the value corresponding to the demand created by Origami Pharma.
Creating a counter value to Taima through cannabis production will allow for a recurring demand that will guarantee some kind of stability. Every increase in production will act as a lever on the price. The financial flows resulting from these transactions will occur in Taima.
The principle of taima is the principle of created supply and demand. Linking the value creation created by the repeated production of medicinal or recreational cannabis plants to Taima will allow it to expand. While the market is facing a shortage of supply, demand is constantly expanding.
The benefits of Taima token holders lie in the purchase of a crypto designed to allow them to invest directly or indirectly in the cannabis industry. A payment token designed to increase value simultaneously with the price of medicinal and recreational cannabis and the expansion of Origami Pharma SA.
Increasing the value of the token in case of price inflation and possibility of resale in private markets
Interact with the medical cannabis industry and join the adventure directly or indirectly
Taking advantage of future opportunities that will be developed by Ashita during the Taima initiative
Contract Address
4sUzhG72Y8qHAmUZBM8hiTWjCU5j3pZgkRztJGLRmwGW
Token Distribution
- Issuer / Ashita = 20%
- Financing Project / Origami = 50%
- Management Team = 10%
- Marketing link = 10%
- Reserve = 10%
Whitepaper
Corporate and Private Investor Sales
Pre ICO
ICO
Entity creation
Listing on exchanges
Start Swissmedic verification
GMP verification
License verification
Start of production 50 tons per year